Summary: H. pylori and precancerous conditions

Marcis Leja

Postgraduate Teaching Programme Barcelona 2026 | Presentation

Stomach & H. Pylori

October 17, 2026

The speaker summarized current Helicobacter pylori and gastric disease management, highlighting upcoming guideline updates including Maastricht Florence guidelines expected by year-end and new autoimmune gastritis guidelines anticipated next year.

KEY POINTS

- The speaker stated that Maastricht six Florence guidelines will be updated by the end of this year, with the next Maastricht Florence meeting occurring within weeks.
- Clinicians should use non-invasive tests when appropriate and always check for successful eradication following treatment, as missing Helicobacter can lead to gastric cancer and ulcer disease.
- Quadruple therapy is returning as first-line treatment in most countries, and treatment should be tailored for resistance unless quadruple therapy is used.
- The speaker noted that molecular testing for resistance is the current state of the art, though stool antigen testing for resistance may become available in the future.
- A guideline on autoimmune gastritis is expected next year, addressing the need for definitions and diagnostic and surveillance strategies.
- A Helicobacter screen and treat guideline for gastric cancer prevention is expected to be finalized by the end of next year.

VIEW THIS CONTENT ON GUTFLIX

https://gutflix.eu/search/d/c54a2dae-d14f-11f1-a3e0-daaa6dbee0a2

AI-generated summary

This summary was generated by an AI large language model based on the content transcript. It is for informational purposes only and should not be considered a substitute for clinical judgment. Always rely on your professional expertise and the full clinical context when making clinical decisions.